Floatz logo

CD16/IL15/CD33 TRISPECIFIC KILLER CELL ENGAGER

Systemic Mastocytosis

GT Biopharma, Inc.protein_peptidePhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Systemic Mastocytosis cohort.

Asset / SponsorPhaseRating
Imatinib
Novartis Pharmaceuticals
Phase 2B
Avapritinib
Blueprint Medicines Corporation
Phase 2B
Brentuximab Vedotin
Jason Robert Gotlib
Phase 2B
Denileukin Diftitox
M.D. Anderson Cancer Center
Phase 2CCC
Bezuclastinib
Cogent Biosciences, Inc.
Phase 2CCC

View all 15 →

Same molecule, other indications

CD16/IL15/CD33 TRISPECIFIC KILLER CELL ENGAGER is also rated in:

myelodysplastic syndromeDormant
CCC
Indicative ·
48 / 100
View asset →
mast cell leukemiaDormant
CCC
Indicative ·
48 / 100
View asset →
acute myeloid leukemiaDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →